Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide + ADT as Neo-Adjuvant Treatment in High Risk Localized Prostate Cancer
NCT07450599Phase 2Recruiting
- Sponsor
- Bayer
- Start
- Apr 2026
- Primary completion
- Oct 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Started Apr 2026; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07450599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07450599.